Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- JCR, Acumen Hook Up to Develop BBB-Penetrating Alzheimer’s Therapy
July 16, 2025
- Otsuka Bags Autoimmune Antibody Drug from Swedish Biotech
July 16, 2025
- Global Pharma Market Surges 9% to US$1.6 Trillion in 2024, Ozempic Overtakes Humira: IQVIA
July 16, 2025
- Asahi Kasei Sharpens Acquisition Focus in Pharma Biz as Envarsus LOE Looms
July 15, 2025
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- FDA Rejects Capricor/Nippon Shinyaku’s DMD Cell Therapy, Seeking More Data
July 15, 2025
- Eisai Launches Gout Drug Urece in China
July 15, 2025
- Japan’s Feliqs to Relocate Headquarters to US, Launch PIb for ROP Drug
July 15, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Merck Japan Joins Hands with Kawasaki City Incubator to Support Startups
July 15, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Toho, Teijin, and Itochu to Jointly Build Regenerative Medicine Ecosystem
July 14, 2025
- Solasia Invests in Sweden’s Isofol as Colorectal Cancer Trials Resume
July 14, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
- More Firms Signal Interest in Meiji-Daito Consortium to Revamp Generic Production
July 14, 2025
- Espha President Signals Move Toward Novel Drug Development amid Group Shift
July 11, 2025
- Izervay US Sales Reach 15.9 Billion Yen in April-June: Astellas
July 11, 2025
- Taiho’s DMD Drug TAS-205 Falls Short in PIII Trial
July 9, 2025
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…